康弘药业
(002773)
| 流通市值：137.41亿 | | | 总市值：184.42亿 |
| 流通股本：6.85亿 | | | 总股本：9.20亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,411,293,193.61 | 2,294,131,650.05 | 1,092,784,087.91 | 3,957,459,641.68 |
| 营业收入 | 3,411,293,193.61 | 2,294,131,650.05 | 1,092,784,087.91 | 3,957,459,641.68 |
| 二、营业总成本 | 2,311,766,338.66 | 1,512,181,562.51 | 658,811,628.42 | 2,807,068,148.65 |
| 营业成本 | 345,306,027.89 | 234,071,095.54 | 114,856,552.26 | 438,408,929.52 |
| 税金及附加 | 42,565,790.28 | 30,927,987.79 | 13,200,291.65 | 56,082,041.98 |
| 销售费用 | 1,287,805,702.52 | 857,730,094.38 | 387,756,159.6 | 1,470,869,100.56 |
| 管理费用 | 340,307,482.38 | 228,633,284.86 | 95,452,003.64 | 472,383,257.5 |
| 研发费用 | 342,158,088.75 | 192,874,128.61 | 63,845,609.61 | 421,678,043.03 |
| 财务费用 | -46,376,753.16 | -32,055,028.67 | -16,298,988.34 | -52,353,223.94 |
| 其中:利息收入 | 47,008,183.2 | 31,191,032.58 | 15,419,989.88 | 52,503,037.47 |
| 加:公允价值变动收益 | -1,387,200 | -969,600 | 268,800 | -832,800 |
| 加:投资收益 | 20,318,174.16 | 19,266,908.69 | -53,158.67 | 45,031,602.19 |
| 资产处置收益 | 14,591.48 | 13,972.01 | - | 9,026.5 |
| 资产减值损失(新) | -746,316.13 | -746,316.13 | - | -230,528.34 |
| 信用减值损失(新) | -1,983,250.5 | -2,754,908.7 | -356,208.51 | -1,317,213.7 |
| 其他收益 | 32,979,760.34 | 23,769,529.72 | 12,706,363.11 | 68,016,071.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,148,722,614.3 | 820,529,673.13 | 446,538,255.42 | 1,261,067,651.4 |
| 加:营业外收入 | 2,339,734.71 | 1,013,868.69 | 249,109.89 | 1,372,815.49 |
| 减:营业外支出 | 12,891,848.86 | 4,245,643.66 | 805,676.37 | 28,523,493.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,138,170,500.15 | 817,297,898.16 | 445,981,688.94 | 1,233,916,973.28 |
| 减:所得税费用 | 173,280,670.12 | 130,761,803.92 | 74,506,590.89 | 202,793,059.07 |
| 六、净利润 | 964,889,830.03 | 686,536,094.24 | 371,475,098.05 | 1,031,123,914.21 |
| 持续经营净利润 | 964,889,830.03 | 686,536,094.24 | 371,475,098.05 | 1,031,123,914.21 |
| 归属于母公司股东的净利润 | 973,711,578.04 | 692,220,039.94 | 373,521,473.06 | 1,044,765,761.76 |
| 少数股东损益 | -8,821,748.01 | -5,683,945.7 | -2,046,375.01 | -13,641,847.55 |
| (一)基本每股收益 | 1.06 | 0.75 | 0.41 | 1.14 |
| (二)稀释每股收益 | 1.06 | 0.75 | 0.41 | 1.14 |
| 八、其他综合收益 | -148,087.22 | -470,338.38 | -586,682.08 | -291,301.28 |
| 归属于母公司股东的其他综合收益 | -148,087.22 | -470,338.38 | -586,682.08 | -291,301.28 |
| 九、综合收益总额 | 964,741,742.81 | 686,065,755.86 | 370,888,415.97 | 1,030,832,612.93 |
| 归属于母公司股东的综合收益总额 | 973,563,490.82 | 691,749,701.56 | 372,934,790.98 | 1,044,474,460.48 |
| 归属于少数股东的综合收益总额 | -8,821,748.01 | -5,683,945.7 | -2,046,375.01 | -13,641,847.55 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |